Chronic lymphocytic leukemia (CLL) is a type of blood cancer in which abnormal lymphocytes, most commonly B lymphocytes, accumulate in the blood, bone marrow, lymph nodes, and spleen. CLL usually develops slowly and may not cause symptoms early on.
The disease can affect the normal production and function of blood cells, potentially leading to anemia, increased susceptibility to infections, or low platelet counts. CLL is closely related to small lymphocytic lymphoma (SLL), with the distinction primarily based on where the abnormal lymphocytes are found.
A timely diagnosis helps determine the extent and biological characteristics of CLL and whether treatment is needed. Not every person diagnosed with CLL needs immediate treatment. Patients without symptoms or with stable disease may be managed with active surveillance, including regular blood tests and clinical assessments.
Causes
Risk Factors
CLL treatment has advanced with targeted therapies and molecular risk assessment, including BTK inhibitors and the BCL2 inhibitor venetoclax, which may be combined with anti-CD20 antibodies. Genetic and molecular testing, including TP53 abnormalities and IGHV mutation status, helps guide treatment selection, while newer options such as the non-covalent BTK inhibitor pirtobrutinib and cellular therapies expand treatment options for selected patients with relapsed or refractory CLL.
Active surveillance: Patients with early or asymptomatic CLL may be monitored regularly without immediate treatment.
Combination therapy: Targeted medicines may be combined with antibodies or other agents depending on the patient's disease characteristics.
Chemotherapy : Traditional chemotherapy has a more limited role than in the past but may still be considered in specific circumstances.
Cost Start From 300Explore Options
CAR-T Cell Therapy : It is specifically approved as a highly effective option for adults with relapsed or refractory CLL who have already exhausted standard BTK and BCL-2 inhibitor treatments.
Cost Start From 80000Explore Options
Stem cell transplantation : Allogeneic stem cell transplantation may be considered for a small number of carefully selected patients with high-risk, treatment-resistant disease.
Cost Start From 11500Explore Options
MediRehab (a chain of Rehab centres, part of MediGence) provides comprehensive rehabilitation services designed to support Chronic Lymphocytic Leukemia (CLL) patients in India. These services include:









Mumbai, India
Sterling Wockhardt Hospital located in Mumbai, India is accredited by NABH. Also listed below are some of the most prominent infrastructural details:

Hyderabad, India
Star Hospitals located in Hyderabad, India is accredited by NABH, NABL. Also listed below are some of the most prominent infrastructural details:

Gurgaon, India
Medanta – The Medicity, Gurugram, founded by renowned cardiac surgeon Dr. Naresh Trehan, is a leading multi-super speciality hospital offering advanced yet affordable healthcare. Spread across a 43-acre campus, it houses 1,391 beds, 270 ICU beds, 40 operation theatres, and 900+ doctors across 30+ specialities. Accredited by JCI, NABH, and NABL, Medanta is designed per American Institute of Architects’ healthcare guidelines. Recognised as the Best Private Hospital in India (2020–2025) and among the World’s Top 250 Hospitals (Newsweek 2024), it excels in Cardiac Care, Cancer, Neurosciences, Gastro, Orthopaedics, and Renal Care, ensuring world-class, collaborative, and compassionate treatment.
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome